Key Takeaways Researchers at MUSC report that engineered mesenchymal stem cells reversed new-onset type 1 diabetes in mice, pointing to the disease’s immune response rather than just its symptoms. The cells were modified to overexpress a protein called alpha-1 antitrypsin, which calmed the autoimmune attack and protected insulin producing beta
Key Takeaways Stem cell therapy can slow cellular aging by targeting the immune system dysfunction and chronic inflammation that drive the aging process at the cellular level. Growth factors released by mesenchymal stem cells (MSCs) support boosting collagen, repairing damaged tissue, and improving skin quality from within. Findings show improvements
Key Takeaways The realistic goals of stem cell therapy for MS are slowing disease activity, reducing fatigue, and improving mobility, not reversing all past damage. Mesenchymal stem cells (MSCs) calm the immune system and protect nerve fibers. Hematopoietic stem cell transplant (HSCT) goes further, aiming to reset the immune system
Quick Summary A 2026 Nature study (MATCH trial) shows autologous macrophage therapy may improve transplant‑free survival in cirrhosis. After 4 years, ~70% of treated patients were alive without liver transplant vs. ~40% in standard care. The treatment uses the patient’s own immune cells (macrophages) to reduce inflammation and support repair.
Quick Summary Family support is essential for recovery after cell-based therapy for hypoxic brain damage. Families help with daily rehabilitation exercises, motor function practice, medication schedules, and emotional support. Recovery takes months or years, and consistent family involvement improves both short-term and long-term neurological outcomes alongside treatments like mesenchymal stem
Quick Summary TreeFrog Therapeutics announced preclinical data for TFG‑001, a 3D neural microtissue therapy for Parkinson’s disease. The approach aims to replace damaged dopamine‑producing neurons. Preclinical models showed rapid dopamine release, nerve regrowth, and motor recovery. However, the work is still preclinical; a Clinical Trial Application is expected in 2027.
Quick Summary New 2026 Phase 2 data for BRTX-100 (autologous mesenchymal stem cell therapy for chronic lumbar disc disease) shows sustained pain and functional improvements at 52 weeks: 56% of evaluable patients had ≥50% VAS pain reduction, 64% had ≥50% ODI disability improvement. Safety data reported no dose-limiting toxicities or
Quick Summary Stem cell therapy is making measured progress toward treating age-related diseases like vision loss, frailty, and Parkinson’s, but broad age reversal remains unproven. Recent clinical trials show improved mobility in frailty patients, while Parkinson’s and vision repair trials aim to replace specific damaged cells. However, safety risks persist,
Quick Summary Stem cell therapy for autism aims to reduce brain inflammation, modulate the immune system, and support nerve cell communication. Types of stem cells studied include umbilical cord derived cells, bone marrow stem cells, and umbilical cord blood cells. Early clinical trials show potential improvements in social interaction and
Quick Summary Stem cell therapy for Alzheimer’s uses mesenchymal stem cells (MSCs), neural stem cells (NSCs), or induced pluripotent stem cells (iPSCs) to repair damaged brain cells, reduce inflammation, and support the central nervous system. Early-stage patients may see improved memory and slower decline, but treatment is not yet a
